VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 03, 2007 -- Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, today announced the results of a study conducted by The University of Texas M. D. Anderson Cancer Center to evaluate the ability of CTCE-9908 to inhibit the metastasis and growth of the primary tumor of a human breast cancer in preclinical models. The study concluded that treatment with the Company's CXCR4 antagonist, CTCE-9908, significantly reduced metastases and primary tumor growth in preclinical models of breast cancer. The effects of anti-metastasis could be due to inhibition of tumor cell homing; however, inhibition of primary tumor growth may indicate involvement of other mechanisms.
